A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
Authors
Keywords
-
Journal
CANCER TREATMENT REVIEWS
Volume 120, Issue -, Pages 102628
Publisher
Elsevier BV
Online
2023-09-20
DOI
10.1016/j.ctrv.2023.102628
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2023) L.E. Hendriks et al. ANNALS OF ONCOLOGY
- Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer
- (2022) Takamasa Koga et al. CANCER SCIENCE
- Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
- (2022) Yasir Y. Elamin et al. CANCER CELL
- Phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations.
- (2022) Alexander I. Spira et al. JOURNAL OF CLINICAL ONCOLOGY
- Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
- (2022) Arsela Prelaj et al. Frontiers in Oncology
- High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
- (2022) Fenneke Zwierenga et al. LUNG CANCER
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
- (2021) Gregory J. Riely et al. Cancer Discovery
- Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
- (2021) Mahlet Z. Tamirat et al. Cancers
- Original study: EGFR Exon 20 Insertion Mutations: clinicopathological characteristics and treatment outcomes in advanced non-small-cell lung cancer
- (2021) Jose Luis Leal et al. Clinical Lung Cancer
- Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)
- (2021) Jonathan W. Riess et al. Clinical Lung Cancer
- Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
- (2021) Arsela Prelaj et al. EUROPEAN JOURNAL OF CANCER
- P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC
- (2021) T. Agrawal et al. Journal of Thoracic Oncology
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- (2021) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.
- (2021) Bianca van Veggel et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
- (2021) Hiroyuki Yasuda et al. LUNG CANCER
- A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
- (2021) Christos Chouaid et al. Targeted Oncology
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
- (2021) Caicun Zhou et al. JAMA Oncology
- ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.
- (2020) Zofia Piotrowska et al. JOURNAL OF CLINICAL ONCOLOGY
- Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.
- (2020) Xiuning Le et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
- (2020) Guangjian Yang et al. LUNG CANCER
- Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
- (2020) Guang-Jian Yang et al. LUNG CANCER
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
- (2019) Wenfeng Fang et al. BMC CANCER
- Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations
- (2019) Jenn-Yu Wu et al. Clinical Lung Cancer
- TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
- (2019) Hibiki Udagawa et al. MOLECULAR CANCER RESEARCH
- Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
- (2019) Mahlet Z. Tamirat et al. PLoS One
- Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
- (2019) B. van Veggel et al. LUNG CANCER
- Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer
- (2018) Jonathan W. Riess et al. Journal of Thoracic Oncology
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- (2018) Jacqulyne P. Robichaux et al. NATURE MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
- (2018) Seonggyu Byeon et al. Cancer Research and Treatment
- Activity of the Hsp90 inhibitor Luminespib Among Non-Small Cell Lung Cancers Harboring EGFR Exon 20 Insertions
- (2018) Z Piotrowska et al. ANNALS OF ONCOLOGY
- EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)
- (2018) Andrés F. Cardona et al. LUNG CANCER
- Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
- (2015) Yuliana Yosaatmadja et al. JOURNAL OF STRUCTURAL BIOLOGY
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
- (2015) A. N. Hata et al. Cancer Discovery
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
- (2013) Geoffrey R. Oxnard et al. Journal of Thoracic Oncology
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
- (2013) M. E. Arcila et al. MOLECULAR CANCER THERAPEUTICS
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More